Navidea Biopharmaceuticals Announces the Presentation of Data at Society of Nuclear Medicine Annual Meeting in June

-- Clinical trial data from oncology and Alzheimer’s disease product candidates to be presented --

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek and AZD4694 programs were accepted for presentation at the Society of Nuclear Medicine Annual Meeting from June 9-13 in Miami, Florida. Details of the presentations from the Phase 3 clinical studies investigating Lymphoseek® (Kit for the Preparation of Technetium Tc 99m Tilmanocept for Injection) in head and neck cancer, breast cancer, and melanoma and from Phase 1/Phase 2 clinical trials of its Alzheimer’s Disease candidate, AZD4694 are listed below.

Presentation Title: Receptor targeted (CD206) Tc99m-tilmanocept (TIL) provides for enhanced long-term (>24 hr) stable signal localization in lymph nodes and equally stable concordance with early preoperative imaging in melanoma and breast cancer (M/BC). (No. 278)

Author:         Wendy L. Metz, PhD, Navidea Biopharmaceuticals
Session, Date: Molecular Imaging in Breast Cancer I
Tuesday, June 12, 8:00 AM

Presentation Title: Comparison of 11C-PiB and 18F-AZD4694 for Aβ imaging in ageing and dementia. (No.149)

Author:         Christopher Rowe, et al, Centre for PET, Austin Health,
Melbourne, VIC, Australia
Session, Date: Quantifying Brain Amyloid Signal - Methods & Challenges
Monday, June 11, Room B217/21, 11:00 AM

Poster Title: Correlation of preoperative lymphoscintigraphy with invivo lymphatic mapping in Phase 3 breast cancer & melanoma clinical studies employing a receptor targeted (CD206) ILM agent Tc99m-tilmanocept. (No.1280)

Author:         Frederick O. Cope, PhD, Navidea Biopharmaceuticals
Session, Date: MTA I: Breast Cancer Posters
Monday, June 11, Exhibit Hall A-B, 2:30 PM - 4:00 PM

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit

Navidea Biopharmaceuticals, Inc.
Brent Larson, Sr. VP & CFO, 614-822-2330

Source: Navidea Biopharmaceuticals, Inc.